Embecta (EMBC) Cash from Investing Activities (2020 - 2026)
Embecta's (EMBC) quarterly Cash from Investing Activities came in at -$500000.0 in Q1 2026, down 400.0% year-on-year from $166666.7 in Q1 2025, and down 105.26% quarter-over-quarter from $9.5 million in Q4 2025.
Embecta (EMBC) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Embecta has disclosed Cash from Investing Activities across 7 years of filings, most recently posting -$500000.0 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$500000.0, down 400.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (up 111.5% YoY), and the FY2025 annual result was -$9.3 million, up 41.14% from the prior year.
- Cash from Investing Activities came in at -$500000.0 for Q1 2026 at Embecta, down from $9.5 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $9.5 million in Q4 2025 to a low of -$9.7 million in Q2 2024.
- The 5-year median for Cash from Investing Activities is -$5.0 million (2022), against an average of -$3.9 million.
- Across the five-year window, Cash from Investing Activities jumped 733.33% in 2025 and slumped 400.0% in 2026, its largest moves.
- Embecta's Cash from Investing Activities stood at -$4.7 million in 2022, then surged by 42.55% to -$2.7 million in 2023, then soared by 44.44% to -$1.5 million in 2024, then surged by 733.33% to $9.5 million in 2025, then plunged by 105.26% to -$500000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$500000.0 (Q1 2026), $9.5 million (Q4 2025), and -$7.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -914.50 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -139.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -96.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -58.03 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -42.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -77.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -90.00 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -131.58 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -133.00 Mn |
| 10 | Embecta | 183.23 Mn | -10.17 Mn | 127.80 Mn | -500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -500,000.00 |
| Mar 31, 2026 | -500,000.00 |
| Dec 31, 2025 | 9.50 Mn |
| Dec 31, 2025 | 9.50 Mn |
| Sep 30, 2025 | -7.30 Mn |
| Sep 30, 2025 | -7.30 Mn |
| Jun 30, 2025 | -400,000.00 |
| Jun 30, 2025 | -400,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | -1.50 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Jun 30, 2024 | -9.70 Mn |
| Jun 30, 2024 | -9.70 Mn |
| Mar 31, 2024 | -3.40 Mn |
| Mar 31, 2024 | -3.40 Mn |
| Dec 31, 2023 | -2.70 Mn |
| Dec 31, 2023 | -2.70 Mn |
| Sep 30, 2023 | -9.20 Mn |
| Sep 30, 2023 | -9.20 Mn |